Reimagining cholinergic therapy for Alzheimer's disease

被引:114
作者
Giacobini, Ezio [1 ]
Cuello, A. Claudio [2 ,3 ]
Fisher, Abraham [4 ]
机构
[1] Univ Geneva, Univ Geneva Hosp, Fac Med, Dept Internal Med Readaptat & Geriatr, CH-1226 Geneva, Switzerland
[2] McGill Univ, Dept Pharmacol, Montreal, PQ H3G 1Y6, Canada
[3] Univ Oxford, Dept Pharmacol, Oxford OX1 3QT, England
[4] Israel Inst Biol Res, Dept Med Chem, IL-74100 Ness Ziona, Israel
关键词
Alzheimer's disease; cholinesterase inhibitors; muscarinic agonists; nerve growth factor; NERVE GROWTH-FACTOR; MILD COGNITIVE IMPAIRMENT; CORTICAL ACETYLCHOLINESTERASE ACTIVITY; POSITRON-EMISSION-TOMOGRAPHY; FACTOR METABOLIC DYSFUNCTION; APOLIPOPROTEIN E-DEFICIENT; CEREBROSPINAL-FLUID LEVELS; BASAL FOREBRAIN ATROPHY; DEEP BRAIN-STIMULATION; NURSING-HOME PLACEMENT;
D O I
10.1093/brain/awac096
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Currently, enhancement of cholinergic neurotransmission via cholinesterase inhibitors represents the main available approach to treat cognitive and behavioural symptoms of the early as well as late stages of Alzheimer's disease. Restoring the cholinergic system has been a primary means of improving cognition in Alzheimer's disease, as four of the six approved therapies are acetylcholinesterase inhibitors. Memantine is an N-methyl-d-aspartate antagonist with a well-documented clinical effect on behavioural symptoms, which is often added to cholinesterase inhibitors to potentiate their effect and aducanumab, targeting the amyloid pathology, has recently been approved. The early, progressive and selective degeneration of the cholinergic system together and its close relation to cognitive deficits supports the use of cholinergic therapy for Alzheimer's disease. This review provides an updated view of the basal forebrain cholinergic system, its relation to cognition and its relevance for therapy of Alzheimer's disease. It deals with the three main aspects that form the basis of the cholinergic-oriented therapy of Alzheimer's disease, its origin, its mechanism of action, its clinical effects, advantages and limits of a cholinergic therapeutic approach. It includes a new and updated overview of the involvement of muscarinic receptors in Alzheimer's disease as well as the recent development of new and highly selective M1 muscarinic receptor agonists with disease-modifying potential. It also addresses the discovery of a novel nerve growth factor metabolic pathway responsible for the trophic maintenance of the basal forebrain system and its deregulation in Alzheimer's disease. It discusses new clinical studies and provides evidence for the long-term efficacy of cholinesterase inhibitor therapy suggesting a disease-modifying effect of these drugs. The classical symptomatic cholinergic therapy based on cholinesterase inhibitors is judiciously discussed for its maximal efficacy and best clinical application. The review proposes new alternatives of cholinergic therapy that should be developed to amplify its clinical effect and supplement the disease-modifying effect of new treatments to slow down or arrest disease progression. Giacobini et al. review the use of cholinesterase inhibitors in Alzheimer's disease, the role of the basal forebrain cholinergic system in cognition, the involvement of the NGF metabolic pathway and the M1 muscarinic receptor in Alzheimer's disease pathology, and potential future therapies with selective M1 muscarinic agonists.
引用
收藏
页码:2250 / 2275
页数:26
相关论文
共 328 条
[1]   A positive allosteric modulator for the muscarinic receptor (M1 mAChR) improves pathology and cognitive deficits in female APPswe/PSEN1ΔE9 mice [J].
Abd-Elrahman, Khaled S. ;
Sarasija, Shaarika ;
Colson, Tash-Lynn L. ;
Ferguson, Stephen S. G. .
BRITISH JOURNAL OF PHARMACOLOGY, 2022, 179 (08) :1769-1783
[2]   Quantification of brain cholinergic denervation in Alzheimer's disease using PET imaging with [18F]-FEOBV [J].
Aghourian, M. ;
Legault-Denis, C. ;
Soucy, J-P ;
Rosa-Neto, P. ;
Gauthier, S. ;
Kostikov, A. ;
Gravel, P. ;
Bedard, M-A .
MOLECULAR PSYCHIATRY, 2017, 22 (11) :1531-1538
[3]   Selective Vulnerability of the Nucleus Basalis of Meynert Among Neuropathologic Subtypes of Alzheimer Disease [J].
Al-Shaikh, Fadi S. Hanna ;
Duara, Ranjan ;
Crook, Julia E. ;
Lesser, Elizabeth R. ;
Schaeverbeke, Jolien ;
Hinkle, Kelly M. ;
Ross, Owen A. ;
Ertekin-Taner, Nilufer ;
Pedraza, Otto ;
Dickson, Dennis W. ;
Graff-Radford, Neill R. ;
Murray, Melissa E. .
JAMA NEUROLOGY, 2020, 77 (02) :225-233
[4]   Compromise of cortical proNGF maturation causes selective retrograde atrophy in cholinergic nucleus basalis neurons [J].
Allard, Simon ;
Jacobs, Marie L. ;
Do Carmo, Sonia ;
Cuello, A. Claudio .
NEUROBIOLOGY OF AGING, 2018, 67 :10-20
[5]   Impact of the NGF Maturation and Degradation Pathway on the Cortical Cholinergic System Phenotype [J].
Allard, Simon ;
Leon, Wanda C. ;
Pakavathkumar, Prateep ;
Bruno, Martin A. ;
Ribeiro-da-Silva, Alfredo ;
Cuello, A. Claudio .
JOURNAL OF NEUROSCIENCE, 2012, 32 (06) :2002-2012
[6]  
Aloe L, 2011, ARCH ITAL BIOL, V149, P175, DOI 10.4449/aib.v149i2.1377
[7]   Gender-related differences in circadian rhythm of rat plasma acetyl- and butyrylcholinesterase: Effects of sex hormone withdrawal [J].
Alves-Amaral, Gracielle ;
Pires-Oliveira, Marcelo ;
Andrade-Lopes, Ana Luiza ;
Chiavegatti, Tiago ;
Godinho, Rosely Oliveira .
CHEMICO-BIOLOGICAL INTERACTIONS, 2010, 186 (01) :9-15
[8]  
Anand R., 2000, NEUROBIOL AGING, V21, P220
[9]  
Anand R., 1998, LONG TERM TREATMENT
[10]   Nerve growth factor selectively regulates expression of transcripts encoding ribosomal proteins [J].
Angelastro, James M. ;
Torocsik, Beata ;
Greene, Lloyd A. .
BMC NEUROSCIENCE, 2002, 3 (1)